Curt Meyer Memorial Prize for German Cancer Researchers Dr. Stephan Mathas and Dr. Martin Janz

They received the prize, worth 10,000 euros, on July 4, 2008 in Berlin for their findings published in Nature Immunology* from Professor Peter Schlag, president of the Berlin Cancer Society (Charité, MDC). Hodgkin's lymphoma, a common form of cancer of the lymphatic system, originates from white blood cells (B cells), which alter their phenotype completely and thus lose all characteristics of a B cell.

Dr. Janz and Dr. Mathas succeeded in decoding the camouflage mechanisms of B cells. Based on these findings, cancer researchers hope that therapy strategies can be developed that will lead to an inhibition of cell growth or to apoptosis of the Hodgkin cells.

The phenotype of Hodgkin lymphoma cells is a riddle that has puzzled pathologists for years. It was not until 1994, some 160 years after the disease was first described by the British physician Sir Thomas Hodgkin (1832), that – using molecular biological methods – scientists discovered that the lymphoma bearing his name originates from the white blood cells, the B cells.

In their article, Dr. Janz and Dr. Mathas of the research group of Professor Bernd Dörken (MDC/Charité) were able to show that several molecular defects in the B cells are responsible for the unique phenotype of the disease. First, in Hodgkin/Reed-Sternberg cells which have evolved from the B cells, the genetic program that steers the maturation of the B cells and maintains their identity is perturbed. One of the main regulators of this program, E2A, is inhibited in Hodgkin lymphoma cells by two antagonists, Id2 and ABF-1. The researchers showed that this mechanism inhibits the gene expression pattern of B cells. Moreover, through the inhibition of E2A in Hodgkin lymphoma cells, genes are switched on that are not typical for B cell development.

Since 1988, the Curt Meyer Memorial Prize has been awarded annually by the Berlin Cancer Society to young scientists from Berlin for outstanding publications in the field of clinical and experimental oncology. The prize is named after Dr. Curt Meyer, a physician and health official of the Berlin Senate who was born in Herleshausen/Thuringia in 1891. In 1944, he was deported to Auschwitz where he as prisoner took care of fellow detainees suffering from epidemic disease. He survived the concentration camp and after the war dedicated himself to public health, including the care of cancer patients. He was the founder of several medical societies, including the Berlin State Committee against Cancer out of which the Berlin Cancer Society has evolved. Curt Meyer died in 1984 at the age of 93.

*Intrinsic inhibition of E2A by ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma

Stephan Mathas1,2*, Martin Janz1,2*, Franziska Hummel2, Michael Hummel3, Brigitte Wollert-Wulf2, Simone Lusatis2 , Ioannis Anagnosto-poulos3, Andreas Lietz2, Mikael Sigvardsson4, Franziska Jundt1,2, Korinna Jöhrens3, Kurt Bommert2, Harald Stein3 and Bernd Dörken1,2

1Max Delbrück Center for Molecular Medicine, Robert-Rossle-Str. 10, 13125 Berlin; 2Hematology, Oncology and Tumorimmunology, Charite, Medical University Berlin, Campus Virchow-Klinikum, Campus Berlin-Buch, Augustenburger Platz 1, 13353 Berlin; 3Institute for Pathology, Charite, Medical University Berlin, Campus Benjamin Franklin, 12200 Berlin; 4Department for Hematopoietic Stemcell Biology, Stemcell Center, Lund University, S221 84 Lund, Sweden

*These authors contributed equally to this work
Barbara Bachtler
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Robert-Rössle-Straße 10; 13125 Berlin; Germany
Phone: +49 (0) 30 94 06 – 38 96
Fax: +49 (0) 30 94 06 – 38 33
e-mail: presse@mdc-berlin.de